Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1994413 | 0.97 | OPRM1 (0.33) | OPRM1DRD2 | |
| SCHEMBL11947844 | 0.85 | CYP2D6 (0.34) | OPRM1DRD2 | |
| SCHEMBL4287458 | 0.83 | — | — | |
| SCHEMBL24900660 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL30632741 | 0.81 | HTR2A (0.31) | — | |
| Hydrochloric Acid SCHEMBL31209348 | 0.81 | HTR2A (0.31) | — | |
| Hydrochloric Acid SCHEMBL26685428 | 0.81 | HTR2A (0.31) | — | |
| SCHEMBL1930118 | 0.77 | — | — | |
| SCHEMBL20224888 | 0.72 | KDM4E (0.36) | OPRM1 | |
| SCHEMBL24332487 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12384789-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2023098825-A1 | SOS1 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11407753-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | OPRM1 3550/4885DRD2 4459/4885NEK2 188/4885 |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | OPRM1 3920/4885DRD2 2629/4885NEK2 877/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | OPRM1 2669/4885DRD2 4787/4885NEK2 521/4885 |
| US-11407753-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | OPRM1 3920/4885DRD2 2629/4885NEK2 877/4885 |
| US-12384789-B2 | Compounds for treating Huntington's disease | HTT, HYPK, FH | OPRM1 3920/4885DRD2 2629/4885NEK2 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.